Table 1.
Comparative analysis of sociological characteristics and clinical information of elderly patients with renal cell carcinoma in different age groups.
| Characters | Cases | 60–64 yr (%) | 65–69 yr (%) | 70–74 yr (%) | 75–79 yr (%) | 80–84 yr (%) | 85+ yr (%) | Chi-square test | |
|---|---|---|---|---|---|---|---|---|---|
| 4863 (24.97%) | 5025 (25.81%) | 3894 (20.00%) | 2959 (15.20%) | 1804 (9.26%) | 927 (4.76%) | χ2 | P | ||
| Gender | |||||||||
| Male | 12,490 (64.14%) | 3278 (67.41%) | 3280 (65.27%) | 2528 (64.92%) | 1839 (62.15%) | 1053 (58.37%) | 512 (55.23%) | 4768.175 | .000 |
| Female | 6982 (35.86%) | 1585 (32.59%) | 1745 (34.73%) | 1366 (35.08%) | 1120 (37.85%) | 751 (41.63%) | 415 (44.77%) | ||
| Race | |||||||||
| White | 16,057 (82.46%) | 3879 (79.77%) | 4074 (81.07%) | 3245 (83.33%) | 2482 (83.88%) | 1565 (86.75%) | 812 (87.59%) | 129.889 | .000 |
| Black | 2026 (10.40%) | 627 (12.89%) | 611 (12.16%) | 373 (9.58%) | 261 (8.82%) | 111 (6.15%) | 43 (4.64%) | ||
| Others | 1389 (7.13%) | 357 (7.34%) | 340 (6.77%) | 276 (7.09%) | 216 (7.30%) | 128 (7.10%) | 72 (7.77%) | ||
| Diagnosis year | |||||||||
| 2010 | 2939 (15.09%) | 739 (15.20%) | 719 (14.31%) | 570 (14.64%) | 446 (15.07%) | 310 (17.18%) | 155 (16.72%) | 41.197 | .022 |
| 2011 | 3017 (15.49%) | 779 (16.02%) | 745 (14.83%) | 597 (15.33%) | 467 (15.78%) | 304 (16.85%) | 125 (13.48%) | ||
| 2012 | 3219 (16.53%) | 809 (16.64%) | 830 (16.52%) | 613 (15.74%) | 521 (17.61%) | 284 (15.74%) | 162 (17.48%) | ||
| 2013 | 3277 (16.83%) | 786 (16.16%) | 884 (17.59%) | 660 (16.95%) | 483 (16.32%) | 308 (17.07%) | 156 (16.83%) | ||
| 2014 | 3416 (17.54%) | 859 (17.66%) | 883 (17.57%) | 679 (17.44%) | 546 (18.45%) | 286 (15.85%) | 163 (17.58%) | ||
| 2015 | 3604 (18.51%) | 891 (18.32%) | 964 (19.18%) | 775 (19.90%) | 496 (16.76%) | 312 (17.29%) | 166 (17.91%) | ||
| AJCC stage | |||||||||
| I | 11,519 (59.16%) | 3038 (62.47%) | 3106 (61.81%) | 2305 (59.19%) | 1688 (57.05%) | 942 (52.22%) | 440 (47.46%) | 181.709 | .000 |
| II | 1566 (8.04%) | 399 (8.20%) | 424 (8.44%) | 315 (8.09%) | 221 (7.47%) | 142 (7.87%) | 65 (7.01%) | ||
| III | 3694 (18.97%) | 807 (16.59%) | 859 (17.09%) | 765 (19.65%) | 624 (21.09%) | 419 (23.23%) | 220 (23.73%) | ||
| IV | 2693 (13.83%) | 619 (12.73%) | 636 (12.66%) | 509 (13.07%) | 426 (14.40%) | 301 (16.69%) | 202 (21.79%) | ||
| T stage | |||||||||
| T1 | 12,093 (62.31%) | 3151 (64.80%) | 3224 (64.16%) | 2411 (61.92%) | 1785 (60.32%) | 1023 (56.71%) | 499 (53.83%) | 135.278 | .000 |
| T2 | 2022 (10.42%) | 514 (10.57%) | 542 (10.79%) | 399 (10.25%) | 288 (9.73%) | 187 (10.37%) | 92 (9.92%) | ||
| T3 | 4604 (23.72%) | 1063 (21.86%) | 1108 (22.05%) | 958 (24.60%) | 777 (26.26%) | 429 (23.78%) | 269 (29.02%) | ||
| T4 | 690 (3.56%) | 135 (2.78%) | 151 (3.00%) | 126 (3.24%) | 109 (3.68%) | 102 (5.65%) | 67 (7.23%) | ||
| N stage | |||||||||
| N0 | 17,933 (92.18%) | 4520 (92.95%) | 4645 (92.44%) | 3617 (92.89%) | 2702 (91.31%) | 1646 (91.24%) | 803 (86.62%) | 67.217 | .000 |
| N1 | 1147 (5.90%) | 270 (5.55%) | 303 (6.03%) | 205 (5.26%) | 167 (5.64%) | 116 (6.43%) | 86 (9.28%) | ||
| N2 | 136 (0.70%) | 17 (0.35%) | 22 (0.44%) | 35 (0.90%) | 26 (0.88%) | 20 (1.11%) | 16 (1.73%) | ||
| N3 | 9 (0.05%) | 2 (0.04%) | 4 (0.08%) | 0 (0.00%) | 2 (0.07%) | 0 (0.00%) | 1 (0.11%) | ||
| NX | 229 (1.18%) | 54 (1.11%) | 51 (1.01%) | 37 (0.95%) | 44 (1.49%) | 22 (1.22%) | 21 (2.27%) | ||
| M stage | |||||||||
| MO | 17,239 (88.53%) | 4302 (88.46%) | 4474 (89.03%) | 3477 (89.29%) | 2619 (88.51%) | 1584 (87.80%) | 783 (84.47%) | 19.520 | .002 |
| M1 | 2233 (11.47%) | 561 (11.54%) | 551 (10.97%) | 417 (10.71%) | 340 (11.49%) | 220 (12.20%) | 144 (15.53%) | ||
AJCC = American Joint Committee on cancer.